
U-M’s Zhen Xu, histotripsy co-inventor, honored with endowed professorship from Li Ka Shing Foundation
Foundation looks to support histotripsy research at the place it was invented.
Foundation looks to support histotripsy research at the place it was invented.
Experts
Zhen Xu, a University of Michigan pioneer in developing the tumor-destroying histotripsy treatment, will expand her partnership with the Hong Kong-based Li Ka Shing Foundation (LKSF) through a new $2.5 million endowed professorship.
It’s a partnership designed to be the means to an end—of cancer.
On Friday, Xu was honored with a Li Ka Shing Endowed Professorship of Biomedical Engineering at U-M. Foundation leaders want to continue and deepen their support of histotripsy at the place where it was invented. A ceremony was held to mark the occasion at the Gerald R. Ford Presidential Library.
Endowed professorships are funded by donors and provide additional resources to acknowledge outstanding research, teaching and service. They are among the highest honors Michigan Engineering can award a faculty member. Mr. Li Ka-shing, a famed philanthropist, and Solina Chau, the foundation’s director, met with Xu, a U-M professor of biomedical engineering, in Hong Kong as a new histotripsy device was delivered to a local hospital.
“When we shared the potential of this precise, targeted, effective and painless option for combating cancer with Mr. Li Ka-Shing, his response was straightforward and resolute,” Chau said. “He said ‘This is truly incredible. We should support its research and treatment services wherever possible, and please expedite it.’”
Histotripsy uses precisely-targeted ultrasound pulses to break down targeted tissues such as tumors, leaving miniscule harmless debris that can be absorbed by the body. It’s an alternative treatment for cancers that comes without the risks of surgery and the taxing side effects of chemotherapy and radiation.
Years of research collaboration between Michigan Engineering and Michigan Medicine have helped push histotripsy out of the lab and into the mainstream. The technology is currently being used to treat patients with liver tumors, and human trials are now underway for patients with kidney and pancreatic tumors.
Histotripsy has been commercialized by U-M startup HistoSonics, co-founded by Xu and a group of university engineers and doctors in 2009. And histrotripsy’s potential has amassed an ever-growing group of supporters.
“This has been an amazing journey so far, and it’s the result of the work of so many people,” Xu said. “There have been nearly a hundred people here at U-M that we’ve worked with directly or indirectly, and HistoSonics now employs almost 200 people. And now we have people like Mr. Li Ka-Shing and Ms. Solina Chau supporting us along with other donors.
“I used to tell people it takes a village, but that’s not enough. It takes an army.”
Li Ka-shing, Chau and the foundation are no strangers to U-M, having now given nearly $10 million to projects at the College of Engineering and Michigan Medicine. Those include:
In the coming months, LKSF officials are looking to expand their current relationship with Michigan Medicine as well. The foundation plans a $4 million donation that will fund a new endowed research professorship and new research in liver cancer diagnosis, treatment and prevention.
“We extend our deepest gratitude to the Li Ka Shing Foundation for their steadfast support of our programs,” said Karen A. Thole, the Robert J. Vlasic Dean of Engineering and a professor of mechanical engineering and aerospace engineering. “Together, through this invaluable partnership, we are turning the promise of transforming the lives of patients and their families around the globe into a tangible reality.”
Xu’s journey toward histotripsy began as she worked toward her master’s (2003) and doctorate (2005) degrees at U-M in biomedical engineering. She worked with the late Charles Cain (PhD EE ’72), a distinguished BME professor and a founder of the U-M Biomedical Engineering Department.
Cain devoted much of his career attempting to use soundwaves as a “knife-less surgical approach” for treating all manner of maladies. Xu’s work in the lab helped make that vision a reality.
The result can be seen in HistoSonics’ Edison Histotripsy System.
“It’s taken over 20 years to realize histotripsy’s potential in routine clinical care and it’s humbling to represent a technology that is changing the paradigm in cancer care and likely human health on a larger scale,” said Mike Blue, HistoSonics’ CEO and president. “Demand from patients, physician users, and hospital systems across the country is a testament to the magnitude of Zhen’s invention.
“In addition, the recognition of histotripsy’s profound importance from the Li Ka Shing Foundation has accelerated adoption and access to patients in need across the globe, for which we are very grateful.”
Late in 2024, Xu was named a fellow of the National Academy of Inventors and a fellow of the Institute of Electrical and Electronics Engineers. In November, she travelled to Hong Kong for the Li Ka Shing Foundation’s donation of an Edison Histotripsy System to the Chinese University of Hong Kong.
“Professor Xu’s visionary work in the field of histotripsy has been truly groundbreaking and BME is extremely proud of her achievements,” said Mary-Ann Mycek, the William and Valerie Hall department chair and a professor of biomedical engineering. “We’re grateful to the Li Ka Shing Foundation for its ongoing commitment to our department and the generous support it has provided over the years.
“The endowed professorship reflects both the excellence and impact of Professor Xu’s research, as well as the potential of histotripsy to significantly improve patients’ lives worldwide.”
“The endowed professorship reflects both the excellence and impact of Professor Xu’s research, as well as the potential of histotripsy to significantly improve patients’ lives worldwide.”
Mary-Ann Mycek, the William and Valerie Hall department chair and a professor of biomedical engineering.
Uniquely positioned as a joint department in both the College of Engineering and the Medical School, U-M’s Biomedical Engineering department is a leader in education, research and clinical translation. U-M BME has one of the oldest and largest biomedical engineering departments in the country.